• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Company Profile

Endo Pharmaceuticals Holdings Inc., through its subsidiary, Endo Pharmaceuticals Inc., engages in the research, development, manufacture, marketing, and sale of branded and generic prescription pharmaceuticals in the United States. Its primary products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana and Opana ER, and Percocet for the relief of moderate to severe pain; Voltaren Gel for use in treating pain associated with osteoarthritis; Frova for the acute treatment of migraine headaches in adults; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas for the palliative treatment of advanced prostate cancer; Valstar, a sterile solution for intravesical instillation of valrubicin and BCG-refractory CIS of the bladder; Hydron Implant, a reservoir-based drug delivery system available for parenteral administration; Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; and Sanctura XR to treat OAB symptoms. The company also offers generic products, including Endocet and morphine sulfate. In addition, it provides various development stage products, which primarily comprise Aveed for the treatment of male hypogonadism; Fortesta for testosterone replacement therapy in male hypogonadism; Octreotide implant for the treatment of acromegaly; Urocidin for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing; and Axomadol in Phase II development for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company has a strategic alliance agreement with Penwest Pharmaceuticals Co. Endo Pharmaceuticals Holdings was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania.

ENDP (Endo International PLC)
Last Trade 6.07 Date 2/22/2020
Change % -0.66 % Price Change -0.04
Open 6.1 52 Week High 12.49
High 6.33 52 Week Low 1.97
Low 6.05 Type stock
Volume 3688338 Average Volume 6756339
Prev Close 6.11 Stock Exchange NASDAQ
Bid 6.08 Ask 6.12
Bid Size 60 Ask Size 1
1st Yr Estimated EPS Growth -5.1586 2nd Yr Estimated EPS Growth -0.083
2 Years Forward Earning Yield 0.346 2 Years Forward PE Ratio 2.8905
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA 7.1312
Book Value per Share -2.9169 Book Value Yield -0.4805
Buy Back Yield CAPE Ratio
Cash Return 0.0136 Cash Flow per Share 0.8407
Cash Flow Yield 0.1385 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.3048 EV/EBIT 28.919
EV/EBITDA 8.9326 EV / Free Cash Flow 73.4444
EV / Forward EBIT EV / Forward EBITDA 6.5512
EV / Forward Revenue 2.908 EV / Pre Tax Income
EV / Revenue 2.7981 EV / Total Asset 0.8353
Expected Dividend Growth Rate Free Cash Flow per Share 0.4962
Free Caash Flow Ratio 12.23384 Free Cash Flow Yield 0.0817
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield 0.3773 Forward PE Ratio 2.6504
Forward Return on Asset 0.0528 Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio PB Ratio 10 Year Growth
PB Ratio 3 Year Growth 1.855874 Cash Ratio 3 Year Average 223.41
Price to Cash Flow Ratio 7.22042 PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 43.462642 PE Ratio 10 Year Growth
PE Ratio 10 Year High 324.3 PE Ratio 10 Year Low 4.020478
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg 4.498293
PE Ratio 5 Year Avg 5.035858 PE Ratio 5 Year High 6.208191
PE Ratio 5 Year Low 4.020478 Free Cash Flow Ratio 10 Year Growth 0.040833
Free Cash Flow Ratio 3 Year Avg 9.228582 Price Change 1 Month 1.070547
Price to Cash Ratio 0.901904 Price / EBITDA 1.695471
Price to Sales Ratio 0.466093 Price to Sales Ratio 10 Year Growth -0.119173
Price to Sales Ratio 3 Year Avg 0.571366 Price to Sales Ratio 5 Year Avg 5.035858
Sale per Share 13.0231 Sales Yield 2.1455
Sustainable Growth Rate Tangible Book Value per Share -31.8156
Tangible Book Value per Share 3 year Avg -34.7121 Tangible Book Value per Share 5 year Avg -36.7325
Total Asset per Share 43.3682 Total Yield
Working Capital per Share 4.3277 Working Capital per Share 3 Year Avg 2.0505
Working Capital per Share 5 Year Avg 1.6138 Beta 2.666237